Researchers advance ovarian cancer detection using cfDNA fragmentomes and protein biomarkers 🔬💉🌍 www.news-medical.net/news/2024100...#OvarianCancer#EarlyDetection#Cancer#cfDNA#Biomarkers#DELFIPro#WomensHealth#CancerScreening#Oncology#Medical
Researchers developed a groundbreaking method to detect ovarian cancer early by analyzing cfDNA fragmentomes and protein biomarkers, significantly improving sensitivity and specificity over existing a...
The evidence is still alive in your blood. A cfDNA test and some Fluconazole will show the truth.
Tracking clonal evolution of drug resistance in ovarian cancer patients by exploiting structural variants in cfDNA www.biorxiv.org/content/10.1101/2024.08.21.609031v1
Drug resistance is the major cause of therapeutic failure in high-grade serous ovarian cancer (HGSOC
Tracking clonal evolution of drug resistance in ovarian cancer patients by exploiting structural variants in cfDNA www.biorxiv.org/content/10.1101/2024.08.21.609031v1
Drug resistance is the major cause of therapeutic failure in high-grade serous ovarian cancer (HGSOC
Total plasma cfDNA methylation in kidney transplant recipients provides insight into acute allograft rejection pathophysiology www.medrxiv.org/content/10.1101/2024.08.17.24312147v1
Background: Acute rejection threatens kidney allograft longevity. Cell-free DNA (cfDNA) is a real-ti
Next-Generation Sequencing August 2024 -- cfDNA special issue open.substack.com/pub/albertvi...
News for cfDNA sequencing which has important implications for Early Cancer Screening
cfDNA UniFlow: A unified preprocessing pipeline for cell-free DNA data from liquid biopsies www.medrxiv.org/content/10.1101/2024.06.01.24308210v1
Background: Cell-free DNA (cfDNA), a broadly applicable biomarker commonly sourced from urine or blo
ROLE OF cfDNA AND ctDNA TO IMPROVE THE RISK STRATIFICATION AND THE DISEASE FOLLOW-UP IN PATIENTS WITH ENDOMETRIAL CANCER: TOWARDS THE CLINICAL APPLICATION www.medrxiv.org/content/10.1101/2024.05.20.24307623v1
Introduction: In the past years, there has been a rise on advanced endometrial cancers (EC) patients
